Gelatin capsules deliver their contents to the stomach, while delayed‐release (DR) capsules are designed to allow delivery to the small intestine. This study evaluated the gastrointestinal release site of DR capsules in six healthy adult dogs compared to gelatin capsules. Both gelatin and DR capsules were filled with barium‐impregnated polyethylene spheres (BIPS™), and following enteral administration, release site was assessed using abdominal radiographs at baseline, immediately after ingestion, 15 min post‐ingestion, 30 min post‐ingestion, and then every 30 min thereafter. The evaluated phases included fasted conditions (phase 1, n = 6), increased meal size (phase 2, n = 2), double encapsulation (phase 3, n = 2), and altered capsule size (phase 4, n = 1). The released site was the stomach in all phases for both capsule types. In phase 1, DR capsules had a significantly prolonged time (median 60 min, range 60–90) to release BIPS™ compared to gelatin capsules (15 min, range 15–30; p = .03). In phase 2 (full meal size), 3 (double encapsulation), and 4 (smaller capsule size) pilot studies, release time was prolonged but still occurred in the stomach. This is similar to the release site for gelatin capsules but differs from the release site for DR capsules in people. This has implications for pharmacologic outcomes for products that are affected by gastric physiology (e.g. fecal microbiota transplantation). Based on this pilot data, clinicians and researchers should not assume DR capsules will allow for intestinal delivery of contents in dogs. Future studies should be conducted on larger and varied populations of dogs.

中文翻译：

---

健康犬延迟释放和明胶胶囊的胃肠道释放位点

明胶胶囊将其内容物输送至胃，而缓释 (DR) 胶囊则设计用于输送至小肠。这项研究评估了六只健康成年犬中 DR 胶囊与明胶胶囊的胃肠道释放部位。明胶和 DR 胶囊均填充有钡浸渍的聚乙烯球 (BIPS™)，肠内给药后，在基线、摄入后立即、摄入后 15 分钟、摄入后 30 分钟和此后每 30 分钟一次。评估阶段包括禁食条件（第 1 阶段、n= 6)，增加膳食量（第 2 阶段，n= 2)，双重封装（第 3 阶段，n= 2），并改变胶囊尺寸（第 4 阶段，n= 1).两种胶囊类型的所有阶段的释放部位都是胃。在第 1 阶段，与明胶胶囊（15 分钟，范围 15-30；中位 60 分钟，范围 15-30；中位 60 分钟，范围 60-90）相比，DR 胶囊释放 BIPS™ 的时间显着延长。p= .03)。在第 2 阶段（全餐量）、第 3 阶段（双胶囊）和第 4 阶段（较小胶囊尺寸）试点研究中，释放时间延长，但仍然发生在胃中。这与明胶胶囊的释放位点相似，但与 DR 胶囊在人体内的释放位点不同。这对于受胃生理学影响的产品（例如粪便微生物群移植）的药理学结果具有影响。根据该试点数据，临床医生和研究人员不应假设 DR 胶囊将允许内容物在狗体内进行肠道输送。未来的研究应该对更大、更多样化的狗群进行。